CCCB selects CLC bio's enterprise platform for next generation sequence analysis

After a thorough head-to-head evaluation against various competing solutions, the Center for Cancer Computational Biology (CCCB) at the Dana-Farber Cancer Institute has selected CLC bio's enterprise platform for next generation sequence analysis.

The CCCB provides analytical support services for labs and researchers at the Dana-Farber Cancer Institute. Over the past two years the CCCB has experienced a significant increase in the number of researchers who are getting into high-throughput sequencing.

"How are we going to support an increasing number of molecular biologists and clinicians who don't have their own bioinformatics resources? That's really what started our evaluation and why we eventually selected CLC bio, after seeing how easy it was for users to do analyses and view their data through CLC bio's user-friendly interface", states Associate Director at the CCCB at the Dana-Farber Cancer Institute, Mick Correll, and continues, " CLC bio's platform also provides versatile deployment opportunities. By giving individual groups access to our central installation of the CLC Genomics Server, they can leverage a powerful enterprise platform while only needing to invest in their own desktop clients."

CLC bio's enterprise platform comprises user-friendly desktop applications, server software for doing the heavy calculations on existing or new powerful central computers, and centralized data sharing and data management. Furthermore, CLC Genomics Server includes an Application Programming Interface (API) for integration and custom plug-in development, making it the most flexible bioinformatics server solution on the market.

CLC bio's enterprise platform for Next Generation Sequencing data analysis, CLC Genomics Server, has been awarded the "Best of Show" prize at the Bio-IT World Conference & Expo 2009 - an award judged by a team of Bio-IT World magazine editors and leading industry experts.